Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab in OA Knee or Hip Pain
NCT00973141Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Sep 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of fulranumab in osteoarthritis (OA) (6 arms), sponsored by Johnson & Johnson. Primary endpoint: Change from baseline in the average osteoarthritis-related pain intensity score at 12 weeks. Started Sep 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00973141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00973141.